A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Feb 2018

At a glance

  • Drugs Cobimetinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Gastric cancer; Male breast cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms CheckMate 032
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Feb 2018 Longer term efficacy and safety results (n=78) for metastatic urogenital cancer patients based on > 2 years of follow-up presented at the 2018 Genitourinary Cancers Symposium
    • 20 Jan 2018 Results assessing outcomes in US refractory gastric or gastroesophageal junction cancer (GC/GEJC) patients by establishing real world (RW) standard of care (SOC) comparators, against placebo in Asian patient (NCT02267343) and NIVO in Western patients (NCT01928394), were presented at the 2018 Gastrointestinal Cancers Symposium.
    • 20 Jan 2018 Results assessing safety profile of Nivolumab in Asian and Western patients of ATTRACTION-2 and CheckMate-032 trials presented at the 2018 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top